CVE-2024-32646

vyper performs double eval of the slice args when buffer from adhoc locations

Description

Vyper is a pythonic Smart Contract Language for the Ethereum virtual machine. In versions 0.3.10 and prior, using the `slice` builtin can result in a double eval vulnerability when the buffer argument is either `msg.data`, `self.code` or `<address>.code` and either the `start` or `length` arguments have side-effects. It can be easily triggered only with the versions `<0.3.4` as `0.3.4` introduced the unique symbol fence. No vulnerable production contracts were found. Additionally, double evaluation of side-effects should be easily discoverable in client tests. As such, the impact is low. As of time of publication, no fixed versions are available.

Category

5.3
CVSS
Severity: Medium
CVSS 3.1 •
EPSS 0.05%
Vendor Advisory github.com
Affected: vyperlang vyper
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2024-32646?
CVE-2024-32646 has been scored as a medium severity vulnerability.
How to fix CVE-2024-32646?
To fix CVE-2024-32646, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2024-32646 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2024-32646 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2024-32646?
CVE-2024-32646 affects vyperlang vyper.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.